Company intelligence / Profile preview

iVexSol

Lexington, Massachusetts, United Statesivexsol.com ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

iVexSol has developed a proprietary platform for rapid, scalable, high-quality lentiviral vector production using stable producer cell lines. This technology addresses bottlenecks in gene therapy manufacturing by enabling on-demand supply of vectors at any scale. The company supports the acceleration of clinical development timelines for its clients but does not have its own therapeutic programs or clinical results.

Modalities: Gene therapy vector (Lentiviral vector)Viral vector production
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on iVexSol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iVexSol.

Explore the full profile